Screening of Human Epidermal Growth Factor Receptor 2 (HER2) Extracellular Domain for Potential Epitopes by Using Immuno-informatics Tools

被引:0
|
作者
Odhar, Hasanain Abdulhameed [1 ]
Ahjel, Salam Waheed [1 ]
Odhar, Zanan Abdulhameed [2 ]
Humadi, Suhad Sami [1 ]
Rayshan, Ali Mahmood [1 ]
Hashim, Ahmed Fadhil [1 ]
机构
[1] Al Zahrawi Univ Coll, Dept Pharm, Karbala, Iraq
[2] Minist Hlth, Baghdad, Iraq
关键词
Breast cancer; HER2; immunotherapy; epitope; peptide vaccine; PREDICTION;
D O I
10.9734/JPRI/2021/v33i22A31383
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The human epidermal growth factor receptor 2 (HER2) is a well-studied oncoprotein that is overexpressed in a considerable proportion of breast cancer patients. The increased expression of this tyrosine kinase receptor is usually associated with poor clinical prognosis in female patients with breast cancer. In these patients, specific response of immune system against HER2 had been observed. This suggests that immunotherapy approaches can be employed for enhancing the response of tumor infiltrating lymphocytes against HER2 in susceptible tumor microenvironment. In this regard, peptide vaccines are considered one of the most affordable immunotherapy modalities due to their low production cost and long-term effect. For this purpose, we have screened the extracellular domain of HER2 crystal for potential B-cells and T-cells epitopes by using different immuno-informatics tools. The output peptides were then refined and filtered according to their antigenicity, allergenicity and vulnerability to selected proteases. Here, we present multiple B-cells and T-cells epitope candidates against HER2 extracellular domain with high antigenicity, low allergenicity and good resistance for selected proteolytic enzymes. These filtered epitopes can be used for design and construction of anti-HER2 peptide vaccine for potential use in HER2 positive breast cancer patients. Additionally, the sequence of linear B-cells epitopes can be used for the design of monoclonal antibody variable region against HER2 extracellular domain.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [11] Human epidermal growth factor receptor 2 (HER2) expression in urothelial carcinomas of the bladder
    Nalwa, A.
    Elhence, A. B. S. P.
    Bharti, J. Naresh
    Rao, M.
    Choudhary, G. Ram
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S170 - S171
  • [12] Development of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2)
    Takei, Junko
    Kaneko, Mika
    Ohishi, Tomokazu
    Sayama, Yusuke
    Kawada, Manabu
    Harada, Hiroyuki
    Kato, Yukinari
    CANCER SCIENCE, 2021, 112 : 545 - 545
  • [13] Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
    Siena, S.
    Sartore-Bianchi, A.
    Marsoni, S.
    Hurwitz, H. I.
    McCall, S. J.
    Penault-Llorca, F.
    Srock, S.
    Bardelli, A.
    Trusolino, L.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1108 - 1119
  • [14] Human epidermal growth factor receptor 2 (HER2/neu) supraexpression in the mammary tumors
    Moise, M.
    Motoc, A.
    Raducan, Andreea
    Raducan, S.
    Niculescu, V.
    Niculescu, M.
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2011, 52 (03): : 1101 - 1105
  • [15] The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker
    Cooke, T
    Reeves, J
    Lannigan, A
    Stanton, P
    EUROPEAN JOURNAL OF CANCER, 2001, 37 : S3 - S10
  • [16] Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
    Siddiqui, Mohammad R.
    Railkar, Reema
    Sanford, Thomas
    Crooks, Daniel R.
    Eckhaus, Michael A.
    Haines, Diana
    Choyke, Peter L.
    Kobayashi, Hisataka
    Agarwal, Piyush K.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [17] Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
    Mohammad R. Siddiqui
    Reema Railkar
    Thomas Sanford
    Daniel R. Crooks
    Michael A. Eckhaus
    Diana Haines
    Peter L. Choyke
    Hisataka Kobayashi
    Piyush K. Agarwal
    Scientific Reports, 9
  • [18] Dual targeting of human epidermal growth factor receptor 2 (HER2) in neoadjuvant trials for operable HER2 positive (HER2+) disease
    Jhaveri K.
    Dang C.
    Current Breast Cancer Reports, 2013, 5 (4) : 321 - 330
  • [19] Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies
    Florido, Roberta
    Smith, Karen L.
    Cuomo, Kimberly K.
    Russell, Stuart D.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (09):
  • [20] Circulating human epidermal growth factor receptor 2 (HER2) is associated with hyperglycaemia and insulin resistance
    Memon, Ashfaque A.
    Bennet, Louise
    Zoller, Bengt
    Wang, Xiao
    Palmer, Karolina
    Sundquist, Kristina
    Sundquist, Jan
    JOURNAL OF DIABETES, 2015, 7 (03) : 369 - 377